Arcus Biosciences (RCUS) closed at $17.85 on November 2, 2026, down 1.9% from the previous close, on volume of 1,254,074 shares (30-day average 2,135,050).
Data as of November 2, 2026.
Arcus Biosciences sets a November 16 London fireside chat at Jefferies Global Healthcare Conference
Market Chameleon (Tue, 3-Nov 4:20 AM ET)
Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
Business Wire (Mon, 2-Nov 4:05 PM ET)
Arcus Biosciences Announces New Employment Inducement Grants
Business Wire (Mon, 26-Oct 4:35 PM ET)
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Business Wire (Wed, 21-Oct 10:53 PM ET)
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
PRNewswire (Wed, 21-Oct 4:26 PM ET)
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Business Wire (Wed, 21-Oct 4:22 PM ET)
Market Chameleon (Tue, 20-Oct 6:26 AM ET)
Market Chameleon (Tue, 20-Oct 4:43 AM ET)
Business Wire (Tue, 20-Oct 8:30 AM ET)
Business Wire (Tue, 22-Sep 8:30 AM ET)
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Arcus Biosciences trades on the NYSE stock market under the symbol RCUS.
As of November 3, 2026, RCUS stock price climbed to $18.75 with 917,666 million shares trading.
RCUS has a beta of 1.12, meaning it tends to be more sensitive to market movements. RCUS has a correlation of 0.05 to the broad based SPY ETF.
RCUS has a market cap of $2.36 billion. This is considered a Mid Cap stock.
Last quarter Arcus Biosciences reported $41 million in Revenue and -$.72 earnings per share. This beat revenue expectation by $19 million and exceeded earnings estimates by $.13.
In the last 3 years, RCUS traded as high as $31.74 and as low as $6.50.
The top ETF exchange traded funds that RCUS belongs to (by Net Assets): IJR, VTI, IWM, XBI, VXF.
RCUS has underperformed the market in the last year with a price return of -4.9% while the SPY ETF gained +11.7%. RCUS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -33.5% and -15.3%, respectively, while the SPY returned +1.3% and -1.6%, respectively.
RCUS support price is $17.05 and resistance is $18.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RCUS shares will trade within this expected range on the day.
